| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.694 | 0.001 | 0.712 | Endothelin receptor antagonist | 0.709 0.001 DBMET00133 0.697 0.001 DBMET00134 0.712 0.001 DBMET01237 | DBMET01237 | |
| 0.652 | 0.001 | 0.66 | Endothelin B receptor antagonist | 0.659 0.001 DBMET00133 0.652 0.001 DBMET00134 0.66 0.001 DBMET01237 | DBMET01237 | |
| 0.622 | 0.001 | 0.648 | Endothelin A receptor antagonist | 0.645 0.001 DBMET00133 0.625 0.001 DBMET00134 0.648 0.001 DBMET01237 | DBMET01237 | |
| 0.539 | 0.025 | 0.571 | Toll-Like receptor 7 agonist | 0.571 0.021 DBMET00133 0.523 0.028 DBMET00134 0.559 0.022 DBMET01237 | DBMET00133 | |
| 0.535 | 0.026 | 0.566 | Toll-Like receptor agonist | 0.566 0.021 DBMET00133 0.517 0.029 DBMET00134 0.553 0.023 DBMET01237 | DBMET00133 | |
| 0.524 | 0.024 | 0.524 | Vasodilator, peripheral | 0.422 0.048 DBMET00133 0.502 0.027 DBMET00134 0.4 0.055 DBMET01237 | ||
| 0.44 | 0.022 | 0.517 | Cardiotonic | 0.517 0.014 DBMET00133 0.437 0.023 DBMET00134 0.516 0.014 DBMET01237 | DBMET00133 | |
| 0.38 | 0.005 | 0.38 | Sodium channel blocker | 0.273 0.014 DBMET00133 0.323 0.008 DBMET00134 0.22 0.026 DBMET01237 | ||
| 0.324 | 0.006 | 0.324 | Sodium channel (voltage-gated) blocker | 0.246 0.016 DBMET00133 0.27 0.012 DBMET00134 0.197 0.03 DBMET01237 | ||
| 0.295 | 0.084 | 0.3 | Sodium/bile acid cotransporter inhibitor | 0.285 0.093 DBMET00133 0.3 0.079 DBMET00134 0.291 0.088 DBMET01237 | DBMET00134 | |
| 0.234 | 0.088 | 0.286 | Aldehyde oxidase inhibitor | 0.187 0.112 DBMET00133 0.286 0.07 DBMET00134 0.23 0.09 DBMET01237 | DBMET00134 | |
| 0.136 | 0.013 | 0.136 | Nav1.7 sodium channel blocker | 0.096 0.025 DBMET00133 0.094 0.026 DBMET00134 0.068 0.046 DBMET01237 | ||
| 0.143 | 0.033 | 0.148 | CC chemokine 6 receptor antagonist | 0.132 0.064 DBMET00133 0.148 0.025 DBMET00134 0.136 0.049 DBMET01237 | DBMET00134 | |
| 0.192 | 0.082 | 0.202 | Histone acetyltransferase inhibitor | 0.202 0.066 DBMET00134 | DBMET00134 | |
| 0.115 | 0.03 | 0.115 | Phosphodiesterase 4D inhibitor | 0.089 0.042 DBMET00133 | ||
| 0.125 | 0.041 | 0.125 | Electron transport complex I inhibitor | 0.106 0.069 DBMET00133 0.102 0.078 DBMET00134 | ||
| 0.078 | 0.009 | 0.078 | Antiviral (Hepatitis D) | 0.075 0.01 DBMET00133 0.075 0.01 DBMET00134 0.072 0.012 DBMET01237 | ||
| 0.18 | 0.122 | 0.197 | Vasodilator | 0.197 0.107 DBMET00134 0.154 0.15 DBMET01237 | DBMET00134 | |
| 0.073 | 0.023 | 0.073 | Phosphodiesterase 4A inhibitor | 0.059 0.03 DBMET00133 | ||
| 0.156 | 0.108 | 0.156 | Non-steroidal antiinflammatory agent | 0.141 0.128 DBMET00134 | ||
| 0.121 | 0.073 | 0.121 | Nav1.3 sodium channel blocker | |||
| 0.058 | 0.014 | 0.058 | GHS receptor agonist | 0.054 0.017 DBMET00133 0.057 0.015 DBMET00134 0.053 0.017 DBMET01237 | ||
| 0.059 | 0.017 | 0.059 | CC chemokine 4 receptor antagonist | 0.052 0.025 DBMET00133 | ||
| 0.08 | 0.04 | 0.08 | Purinergic P2X2 antagonist | 0.063 0.05 DBMET00133 | ||
| 0.123 | 0.086 | 0.123 | Cytokine production inhibitor | |||
| 0.06 | 0.023 | 0.064 | Vanilloid 2 antagonist | 0.05 0.042 DBMET00133 0.064 0.018 DBMET00134 0.054 0.033 DBMET01237 | DBMET00134 | |
| 0.124 | 0.096 | 0.13 | Aurora-C kinase inhibitor | 0.119 0.108 DBMET00133 0.13 0.084 DBMET00134 0.125 0.095 DBMET01237 | DBMET00134 | |
| 0.09 | 0.063 | 0.09 | Hepatocyte growth factor antagonist | 0.083 0.071 DBMET00134 | ||
| 0.082 | 0.057 | 0.084 | Transforming growth factor beta 3 antagonist | 0.077 0.076 DBMET00133 0.084 0.053 DBMET00134 0.078 0.071 DBMET01237 | DBMET00134 | |
| 0.103 | 0.079 | 0.107 | Nav1.5 sodium channel blocker | 0.107 0.073 DBMET00134 | DBMET00134 | |
| 0.089 | 0.075 | 0.09 | Interleukin 12 antagonist | 0.09 0.072 DBMET00134 | DBMET00134 | |
| 0.089 | 0.076 | 0.174 | Bronchodilator | 0.174 0.024 DBMET00133 0.154 0.03 DBMET01237 | DBMET00133 | |
| 0.043 | 0.031 | 0.044 | Guanylate cyclase stimulant | 0.044 0.029 DBMET00134 | DBMET00134 | |
| 0.158 | 0.148 | 0.158 | Tumour necrosis factor alpha release inhibitor | |||
| 0.017 | 0.011 | 0.02 | CC chemokine 9 receptor antagonist | 0.019 0.008 DBMET00133 0.018 0.01 DBMET00134 0.02 0.007 DBMET01237 | DBMET01237 | |
| 0.066 | 0.062 | 0.066 | Nav1.8 sodium channel blocker | |||
| 0.05 | 0.046 | 0.055 | Bombesin 3 receptor antagonist | 0.055 0.039 DBMET00134 | DBMET00134 | |
| 0.036 | 0.032 | 0.036 | Dihydropteroate synthase inhibitor | |||
| 0.112 | 0.108 | 0.112 | Nav1.6 sodium channel blocker | |||
| 0.008 | 0.011 | 0.01 | 2-Acylglycerol O-acyltransferase 2 inhibitor | 0.01 0.007 DBMET00133 0.01 0.006 DBMET01237 | DBMET01237 | |
| 0.1 | 0.105 | 0.104 | Cyclooxygenase 2 inhibitor | 0.104 0.1 DBMET00134 | DBMET00134 | |
| 0.107 | 0.116 | 0.114 | Cyclooxygenase inhibitor | 0.114 0.107 DBMET00134 | DBMET00134 | |
| 0.026 | 0.043 | 0.051 | Purinergic P2X3 antagonist | 0.051 0.01 DBMET00133 0.046 0.013 DBMET01237 | DBMET00133 | |
| 0.074 | 0.092 | 0.08 | Vanilloid agonist | 0.08 0.07 DBMET00134 | DBMET00134 | |
| 0.049 | 0.081 | 0.064 | Bcl2 antagonist | 0.064 0.049 DBMET00134 | DBMET00134 | |
| 0.05 | 0.085 | 0.057 | Bcl-xL inhibitor | 0.057 0.05 DBMET00134 | DBMET00134 | |
| 0.037 | 0.075 | 0.054 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.054 0.037 DBMET00134 | DBMET00134 | |
| 0.096 | 0.158 | 0.116 | Mannose-6-phosphate isomerase inhibitor | 0.116 0.108 DBMET00134 | DBMET00134 | |
| 0.086 | 0.151 | 0.118 | Thrombolytic | 0.118 0.113 DBMET00134 | DBMET00134 | |
| 0.058 | 0.203 | 0.257 | Lipid peroxidase inhibitor | 0.202 0.041 DBMET00133 0.257 0.025 DBMET01237 | DBMET01237 | |
| 0.146 | 0.295 | 0.203 | Histamine release inhibitor | 0.203 0.198 DBMET00134 | DBMET00134 | |
| 0.159 | 0.345 | 0.287 | Cyclophilin D inhibitor | 0.287 0.174 DBMET01237 | DBMET01237 | |
| 0.16 | 0.397 | 0.317 | Antiinflammatory | 0.317 0.2 DBMET01237 | DBMET01237 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |